A Review of the Antiviral Activity of Berberine

References

1. PradityaD. KirchhoffL. BrüningJ. RachmawatiH. SteinmannJ. SteinmannE. Anti-infective properties of the golden spice curcumin.Front. Microbiol.20191091210.3389/fmicb.2019.00912 31130924
   [Google Scholar]
2. KausarS. Said KhanF. Ishaq Mujeeb Ur RehmanM. A review: Mechanism of action of antiviral drugs.Int. J. Immunopathol. Pharmacol.2021352058738421100262110.1177/20587384211002621 33726557
   [Google Scholar]
3. HawkinsT. Understanding and managing the adverse effects of antiretroviral therapy.Antiviral Res.201085120120910.1016/j.antiviral.2009.10.016 19857521
   [Google Scholar]
4. BakerR.E. MahmudA.S. MillerI.F. Infectious disease in an era of global change.Nat. Rev. Microbiol.202220419320510.1038/s41579‑021‑00639‑z 34646006
   [Google Scholar]
5. KhanM.S.A. AhmadI. Herbal medicine: Current trends and future prospects.New look to phytomedicine.Elsevier201931310.1016/B978‑0‑12‑814619‑4.00001‑X
   [Google Scholar]
6. JamalA. Embracing nature’s therapeutic potential: Herbal medicine.Int J Multidiscip Sci Arts20232311712610.47709/ijmdsa.v2i1.2620
   [Google Scholar]
7. ChaughuleR.S. BarveR.S. Role of herbal medicines in the treatment of infectious diseases.Vegetos2023371415110.1007/s42535‑022‑00549‑2 36687385
   [Google Scholar]
8. LoweH. SteeleB. BryantJ. FouadE. ToyangN. NgwaW. Antiviral activity of Jamaican medicinal plants and isolated bioactive compounds.Molecules202126360710.3390/molecules26030607 33503834
   [Google Scholar]
9. StanD. EnciuA.M. MateescuA.L. Natural compounds with antimicrobial and antiviral effect and nanocarriers used for their transportation.Front. Pharmacol.20211272323310.3389/fphar.2021.723233 34552489
   [Google Scholar]
10. ZakaryanH. ArabyanE. OoA. ZandiK. Flavonoids: Promising natural compounds against viral infections.Arch. Virol.201716292539255110.1007/s00705‑017‑3417‑y 28547385
    [Google Scholar]
11. Och A, Podgórski R, Nowak R. Biological activity of berberine—A summary update.Toxins (Basel)2020121171310.3390/toxins12110713 33198257
    [Google Scholar]
12. ChengZ. KangC. CheS. Berberine: A promising treatment for neurodegenerative diseases.Front. Pharmacol.20221384559110.3389/fphar.2022.845591 35668943
    [Google Scholar]
13. KumarA. Ekavali, Chopra K, Mukherjee M, Pottabathini R, Dhull DK. Current knowledge and pharmacological profile of berberine: An update.Eur. J. Pharmacol.201576128829710.1016/j.ejphar.2015.05.068 26092760
    [Google Scholar]
14. GermoushM.O. MahmoudA.M. Berberine mitigates cyclophosphamide-induced hepatotoxicity by modulating antioxidant status and inflammatory cytokines.J. Cancer Res. Clin. Oncol.201414071103110910.1007/s00432‑014‑1665‑8 24744190
    [Google Scholar]
15. OchA. OchM. NowakR. Podgórska D, Podgórski R. Berberine, a herbal metabolite in the metabolic syndrome: The risk factors, course, and consequences of the disease.Molecules2022274135110.3390/molecules27041351 35209140
    [Google Scholar]
16. LiZ. GengY-N. JiangJ-D. KongW-J. Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus.Evid. Based Complement. Alternat. Med.2014201428926410.1155/2014/289264 24669227
    [Google Scholar]
17. LauC.W. YaoX.Q. ChenZ.Y. KoW.H. HuangY. Cardiovascular actions of berberine.Cardiovasc. Drug Rev.200119323424410.1111/j.1527‑3466.2001.tb00068.x 11607041
    [Google Scholar]
18. AkbarM. ShabbirA. RehmanK. AkashM.S.H. ShahM.A. Neuroprotective potential of berberine in modulating Alzheimer’s disease via multiple signaling pathways.J. Food Biochem.20214510e1393610.1111/jfbc.13936 34523148
    [Google Scholar]
19. a DoggrellSA Berberine--a novel approach to cholesterol lowering Expert Opin Investig Drugs2005145683510.1517/13543784.14.5.683 15926873
20. b KongW. WeiJ. AbidiP. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.Nat. Med.200410121344135110.1038/nm1135 15531889
    [Google Scholar]
21. RaufA. Abu-IzneidT. KhalilA.A. Berberine as a potential anticancer agent: A comprehensive review.Molecules20212623736810.3390/molecules26237368 34885950
    [Google Scholar]
22. ZhangB. WangL. JiX. Anti-inflammation associated protective mechanism of berberine and its derivatives on attenuating pentylenetetrazole-induced seizures in zebrafish.J. Neuroimmune Pharmacol.202015230932510.1007/s11481‑019‑09902‑w 31909440
    [Google Scholar]
23. BhattacharjeeK. NathM. ChoudhuryY. Berberine is as effective as the anti-obesity drug Orlistat in ameliorating betel-nut induced dyslipidemia and oxidative stress in mice.Phytomed. Plus20211310009810.1016/j.phyplu.2021.100098
    [Google Scholar]
24. WangJ.T. PengJ.G. ZhangJ.Q. Novel berberine-based derivatives with potent hypoglycemic activity.Bioorg. Med. Chem. Lett.2019292312670910.1016/j.bmcl.2019.126709 31629632
    [Google Scholar]
25. ČerňákováM. KošťálováD. Antimicrobial activity of berberine—a constituent ofMahonia aquifolium.Folia Microbiol. (Praha)200247437537810.1007/BF02818693 12422513
    [Google Scholar]
26. UtamiA.R. MaksumI.P. DeawatiY. Berberine and its study as an antidiabetic compound.Biology (Basel)202312797310.3390/biology12070973 37508403
    [Google Scholar]
27. WangW. LiY. ZhangZ. WeiW. Human immunodeficiency virus-1 core: The Trojan horse in virus–host interaction.Front. Microbiol.202213100247610.3389/fmicb.2022.1002476 36106078
    [Google Scholar]
28. GolmohammadiZ. BoostaniR. SaeidiM. Serum evaluation of human T-lymphotropic virus type 1 and 2 (HTLV-I/II) and human immunodeficiency virus (HIV) in patients with multiple sclerosis (MS).Arch. Neurosci.2023103e13523010.5812/ans‑135230
    [Google Scholar]
29. ZhaW. LiangG. XiaoJ. Berberine inhibits HIV protease inhibitor-induced inflammatory response by modulating ER stress signaling pathways in murine macrophages.PLoS One201052e906910.1371/journal.pone.0009069 20161729
    [Google Scholar]
30. BodiwalaH.S. SabdeS. MitraD. BhutaniK.K. SinghI.P. Synthesis of 9-substituted derivatives of berberine as anti-HIV agents.Eur. J. Med. Chem.20114641045104910.1016/j.ejmech.2011.01.016 21295891
    [Google Scholar]
31. Ruiz-HerreraV.V. Navarro-LaraS.A. Andrade-VillanuevaJ.F. Pilot study on the efficacy and safety of berberine in people with metabolic syndrome and human immunodeficiency virus infection.Int. J. STD AIDS202334141042105210.1177/09564624231196600 37611246
    [Google Scholar]
32. Amini-FarsaniZ. Yadollahi-FarsaniM. ArabS. ForouzanfarF. YadollahiM. AsgharzadeS. Prediction and analysis of microRNAs involved in COVID-19 inflammatory processes associated with the NF-kB and JAK/STAT signaling pathways.Int. Immunopharmacol.202110010807110.1016/j.intimp.2021.108071 34482267
    [Google Scholar]
33. ForouzanfarF. AhmadpoorM. FarahiM.M. The effect of pomegranate juice and sumac consumption in the treatment of outpatients with COVID-19.Mediators Inflamm.20222022111010.1155/2022/6850342 36505757
    [Google Scholar]
34. ForoozanfarE. ForouzanfarM. FarkhondehT. SamarghandianS. ForouzanfarF. ACE2 as a potential target for management of novel coronavirus (nCoV-2019).Curr. Drug Discov. Technol.20211866910.2174/1570163817999201228215911 33371835
    [Google Scholar]
35. ZhangB.Y. ChenM. ChenX.C. Berberine reduces circulating inflammatory mediators in patients with severe COVID-19.Br. J. Surg.20211081e9e1110.1093/bjs/znaa021 33640910
    [Google Scholar]
36. DuncanJ.D. UrbanowiczR.A. TarrA.W. BallJ.K. Hepatitis C virus vaccine: Challenges and prospects.Vaccines (Basel)2020819010.3390/vaccines8010090 32079254
    [Google Scholar]
37. AhadiM. KhoshakhlaghM. MasoudifarN. Interleukin-6 Gene (-174 G>C) polymorphisms in patients with chronic hepatitis C virus; A case-control study.Hepat. Mon.2024241e13930910.5812/hepatmon‑139309
    [Google Scholar]
38. GhasemiF. Ghayour-MobarhanM. GouklaniH. MeshkatZ. Development of preventive vaccines for hepatitis C virus E1/E2 protein.Iran. J. Pathol.201813211312410.30699/ijp.13.2.113 30697280
    [Google Scholar]
39. HungT.C. JasseyA. LiuC.H. Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein.Phytomedicine201953626910.1016/j.phymed.2018.09.025 30668413
    [Google Scholar]
40. BorchersA.T. ChangC. GershwinM.E. GershwinL.J. Respiratory syncytial virus-a comprehensive review.Clin. Rev. Allergy Immunol.201345333137910.1007/s12016‑013‑8368‑9 23575961
    [Google Scholar]
41. AcostaP.L. CaballeroM.T. PolackF.P. Brief history and characterization of enhanced respiratory syncytial virus disease.Clin. Vaccine Immunol.201623318919510.1128/CVI.00609‑15 26677198
    [Google Scholar]
42. MazurN.I. TerstappenJ. BaralR. Respiratory syncytial virus prevention within reach: The vaccine and monoclonal antibody landscape.Lancet Infect. Dis.2023231e2e2110.1016/S1473‑3099(22)00291‑2 35952703
    [Google Scholar]
43. ShinH.B. ChoiM.S. YiC.M. LeeJ. KimN.J. InnK.S. Inhibition of respiratory syncytial virus replication and virus-induced p38 kinase activity by berberine.Int. Immunopharmacol.2015271656810.1016/j.intimp.2015.04.045 25939536
    [Google Scholar]
44. ShtroA.A. GladkovaE.D. GalochkinaA.V. Synthesis of berberine derivatives and their antiviral activity toward respiratory syncytial virus.Med. Chem. Res.202332112325233310.1007/s00044‑023‑03138‑3
    [Google Scholar]
45. SkeltonR.M. HuberV.C. Comparing influenza virus biology for understanding influenza d virus.Viruses2022145103610.3390/v14051036 35632777
    [Google Scholar]
46. YanY.Q. FuY.J. WuS. Anti‐influenza activity of berberine improves prognosis by reducing viral replication in mice.Phytother. Res.201832122560256710.1002/ptr.6196 30306659
    [Google Scholar]
47. BotwinaP. OwczarekK. RajfurZ. Berberine hampers influenza a replication through inhibition of MAPK/ERK pathway.Viruses202012334410.3390/v12030344 32245183
    [Google Scholar]
48. LiuH. YouL. WuJ. Berberine suppresses influenza virus-triggered NLRP3 inflammasome activation in macrophages by inducing mitophagy and decreasing mitochondrial ROS.J. Leukoc. Biol.2020108125326610.1002/JLB.3MA0320‑358RR 32272506
    [Google Scholar]
49. WuY. LiJ. KimY. WuJ. WangQ. HaoY. In vivo and in vitro antiviral effects of berberine on influenza virus.Chin. J. Integr. Med.201117644445210.1007/s11655‑011‑0640‑3 21660679
    [Google Scholar]
50. ColpaniV. Soares FalcettaF. Bacelo BidinottoA. Prevalence of human papillomavirus (HPV) in Brazil: A systematic review and meta-analysis.PLoS One2020152e022915410.1371/journal.pone.0229154 32084177
    [Google Scholar]
51. LiuD. Human papillomaviruses.In: Molecular Medical Microbiology.Elsevier20242547255810.1016/B978‑0‑12‑818619‑0.00111‑8
    [Google Scholar]
52. MahataS. BhartiA.C. ShuklaS. TyagiA. HusainS.A. DasB.C. Berberine modulates AP-1 activity to suppress HPV transcription and downstream signaling to induce growth arrest and apoptosis in cervical cancer cells.Mol. Cancer20111013910.1186/1476‑4598‑10‑39 21496227
    [Google Scholar]
53. HerbeinG. High-risk oncogenic human cytomegalovirus.Viruses20221411246210.3390/v14112462 36366560
    [Google Scholar]
54. LuganiniA. MercorelliB. MessaL. PalùG. GribaudoG. LoregianA. The isoquinoline alkaloid berberine inhibits human cytomegalovirus replication by interfering with the viral Immediate Early-2 (IE2) protein transactivating activity.Antiviral Res.2019164526010.1016/j.antiviral.2019.02.006 30738836
    [Google Scholar]
55. PignoloniB. FiondaC. Dell’OsteV. Distinct roles for human cytomegalovirus immediate early proteins IE1 and IE2 in the transcriptional regulation of MICA and PVR/CD155 expression.J. Immunol.2016197104066407810.4049/jimmunol.1502527 27733551
    [Google Scholar]
56. YeY. LiuX. WuN. Efficacy and safety of berberine alone for several metabolic disorders: A systematic review and meta-analysis of randomized clinical trials.Front. Pharmacol.20211265388710.3389/fphar.2021.653887 33981233
    [Google Scholar]
57. ChoiY.K. Emerging and re-emerging fatal viral diseases.Exp. Mol. Med.202153571171210.1038/s12276‑021‑00608‑9 33953321
    [Google Scholar]